Serum tau protein as a marker of disease activity in enterohemorrhagic Escherichia coli O111-induced hemolytic uremic syndrome

• Published in: Neurochemistry international Vol. 85-86; pp. 24 - 30
• Main Authors: Kuroda, Mondo, Shimizu, Masaki, Inoue, Natsumi, Ikeno, Iku, Nakagawa, Hiroyasu, Yokoi, Ayano, Niida, Yo, Konishi, Michio, Kaneda, Hisashi, Igarashi, Noboru, Yamahana, Junya, Taneichi, Hiromichi, Kanegane, Hirokazu, Ito, Mika, Saito, Shigeru, Furuichi, Kengo, Wada, Takashi, Nakagawa, Masaru, Yokoyama, Hitoshi, Yachie, Akihiro
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.06.2015
• Subjects: Adolescent; Adult; Child; Disease Outbreaks; Encephalopathy; Enterohemorrhagic Escherichia coli; Enterohemorrhagic Escherichia coli - pathogenicity; Escherichia coli Infections - epidemiology; Escherichia coli Infections - pathology; Female; Hemolytic uremic syndrome; Hemolytic-Uremic Syndrome - epidemiology; Hemolytic-Uremic Syndrome - pathology; Humans; Infant; Japan - epidemiology; Magnetic Resonance Imaging; Male; Tau protein; tau Proteins - blood; Japan; Enterohemorrhagic Escherichia coli; Tau protein; Hemolytic uremic syndrome; Encephalopathy
• ISSN: 0197-0186; 1872-9754
• DOI: 10.1016/j.neuint.2015.04.003

•Serum tau protein levels increased markedly in patients with severe EHEC 0111/HUS and encephalopathy.•Changes in serum tau protein levels in patients with EHEC encephalopathy were consistent with abnormalities on brain MRI.•Serum tau protein levels were positively correlated with proinflammatory cytokine levels.•Serum tau protein might be useful to predict and assess disease activity of EHEC encephalopathy. Tau protein levels in cerebrospinal fluid (CSF) and serum are elevated in patients with various central nervous system diseases. We investigated whether serum tau protein levels are useful for predicting and assessing disease activity of acute encephalopathy (AE) in enterohemorrhagic Escherichia coli (EHEC) O111-induced hemolytic uremic syndrome (HUS; EHEC encephalopathy). Serum samples were obtained from 14 patients with EHEC O111/HUS, 20 patients with non-EHEC-related AE, and 20 age- and sex-matched healthy controls. CSF samples were obtained from 2 patients with EHEC encephalopathy and 20 patients with non-EHEC-related AE. Tau protein levels and levels of several proinflammatory cytokines were quantified by enzyme-linked immunosorbent assays. Results were compared with the clinical features of EHEC encephalopathy, including magnetic resonance image (MRI) findings. Serum tau levels in patients with EHEC encephalopathy were significantly elevated compared with those in patients with EHEC O111/HUS without encephalopathy, patients with non-EHEC-related AE, and healthy controls. The ratio of CSF tau levels to serum tau levels was >1.0 in all patients with non-EHEC-related AE but <1.0 in 2 patients with EHEC encephalopathy. Serum tau protein levels increased rapidly and markedly in patients with severe EHEC 0111/HUS and encephalopathy when HUS occurred, but were not elevated in mild patients, even in the HUS phase. Furthermore, changes in serum tau protein levels in patients with EHEC encephalopathy were consistent with abnormalities on brain MRI and were positively correlated with proinflammatory cytokine levels. Our results indicate that serum tau protein might be useful to predict and assess disease activity of EHEC encephalopathy.